Menu
Recruiting NCT07299071

Efficacy of CAD in Screening Colonoscopy to Reduce the Risk of Advanced Adenoma at 3 Years.

No phase Interventional Colonoscopy Colorectal Neoplasms Intestinal Polyps

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Standard colonoscopy, Colonoscopy CADe.
Who it may be relevant to
Registry conditions: Colonoscopy, Colorectal Neoplasms, Intestinal Polyps. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Randomized Controlled Trial Evaluating the Efficacy of CAD in Screening Colonoscopy to Reduce the Risk of Advanced Adenoma at 3 Years.

Overview

The occurrence of interval cancers after colonoscopy raises the possibility of missed lesions. High- performance computer aided diagnosis (CAD) systems have been specially designed for the detection of colorectal lesions (CAD for detection is named CADe). The use of CADe improves adenoma detection in screening colonoscopy. The potential of CADe system in reducing the rate of progression to advanced polyps or interval cancer between two colonoscopies remains still uncertain.

Detailed description

Patients will be enrolled after a pre-colonoscopy consultation and risk-assessment for colorectal cancer. The screening colonoscopy will be performed by an investigator. Patients will be randomized in the endoscopy room after confirmed cecal intubation and quality of bowel preparation. Randomization into two groups: standard colonoscopy vs. colonoscopy with CADe (CAD EYE or GENIUS) (1:1). A follow-up consultation will be scheduled one-month postcolonoscopy for delivery of histological results and then at 3 years in order to organize the next colonoscopy. As part of the study, a new control colonoscopy will be scheduled for patients with high risk of CRC at 3 years. The 3-year control colonoscopy will be performed with the CAD system for all patients. The colonoscopy will be performed by another investigator who does not know the results nor the type of the first colonoscopy (evaluator blinded). In the low-risk group, we will collect follow-up data as part of routine care, including the results of colonoscopies performed outside of the protocol

Interventions

  • Procedure Standard colonoscopy
    Colonoscopy standard (without CADe)
  • Procedure Colonoscopy CADe
    colonoscopy with CADe

Primary outcome measures

  • Advanced adenoma [Time frame: 36 months]
Secondary outcome measures (4)
  • Number of adenoma [Time frame: 36 months]
  • Estimation of the sensitivity of CADx [Time frame: Day0, 36 months]
  • Estimation of the specificity of CADx [Time frame: DAY 0, 36 months]
  • Cost of CADe and classical colonoscopy [Time frame: Day 0, 36 months]

Eligibility criteria

Inclusion criteria

  • Patients over 18 years of age with indication for colonoscopy as part of a screening program, after a positive immunological (FIT) test, and/or for personal or family history of colorectal cancer and/or personal history of colonic adenomas,
  • Written informed consent signed
  • Patients covered by a health-care insurance.

Exclusion criteria

  • Failed complete colonoscopy, defined by the absence of cecal intubation and/or the absence of terminal ileum cauterization
  • Inadequate bowel preparation (Boston bowel preparation score < 6, and/or least at one part of colon with score ≤ 1)
  • An infiltrative tumor was diagnosed during colonoscope insertion time, not accessible to endoscopic resection and likely to require surgical management (a procedure where part of the colon may need to be removed).
  • Patient under guardianship or protection
  • Pregnant women
  • Not fluent in French or illiterate
  • Personal history of inflammatory bowel disease
  • Personal history of genetic predisposition of CRC
  • Personal history of colonic surgery

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Triple blind
Primary purpose
Diagnostic

Study locations

France · 13 centers
  • CH de la Côte Basque — Bayonne
  • CHU Brest la Cavale Blanche — Brest
  • Clinique Paris Bercy — Charenton-le-Pont
  • CHU de Limoges — Limoges
  • Institut Paoli Calmettes — Marseille
  • Clinique Jules Verne — Nantes
  • CHU Nîmes — Nîmes
  • APHP - Hôpital Saint Antoine — Paris
  • … and 5 more centers

Identifiers

NCT: NCT07299071 · CHUBX 2024/48

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗